<PRE>
[Federal Register: June 26, 2002 (Volume 67, Number 123)]
[Notices]               
[Page 43138-43139]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr26jn02-99]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes Of Health

 
Prospective Grant Of Exclusive License: Prophylactic and/or 
Therapeutic Vaccine Against HCV Infection

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a limited field of use exclusive world-wide license to practice the 
invention embodied in U.S. Serial Number 09/763,260, filed February 20, 
2001 (claiming priority to U.S. Provisional Patent Application Serial 
No. 60/097,446, filed August 21, 1998), entitled ``Modified HCV Peptide 
Vaccine'' to Intercell AG of Vienna, Austria. These patent rights are 
assigned to the United States as represented by the Department of 
Health and Human Services.

DATES: Only written comments and/or applications for a license which 
are received by NIH on or before September 24, 2002, will be 
considered.

ADDRESSES: Requests for a copy of this issued patent or applications, 
inquiries, comments, and other materials relating to the contemplated 
license should be directed to: Carol A. Salata, Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3821; 
Telephone: (301) 496-7735 ext 232; Facsimile: (301) 402-0220; E-mail: 
<A HREF="mailto:salatac@od.nih.gov">salatac@od.nih.gov</A>.

[[Page 43139]]


SUPPLEMENTARY INFORMATION: The invention provides immunogenic peptides 
of HCV core protein that elicit an enhanced immune response, methods 
for making these peptides, and methods for using these peptides for a 
variety of therapeutic, diagnostic, and prognostic applications, 
including a vaccine.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
It is anticipated that this license may be limited to the field of use 
as a prophylactic and/or therapeutic vaccine against HCV infection. 
Intercell AG will use an HCV peptide as a component of an HCV vaccine.
    This prospective exclusive license may be granted unless, within 90 
days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    Applications for a license filed in response to this notice will be 
treated as objections to the grant of the contemplated license. 
Comments and objections submitted in response to this notice will not 
be made available for public inspection, and, to the extent permitted 
by law, will not be released under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: June 17, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 02-16088 Filed 6-25-02; 8:45 am]
BILLING CODE 4140-01-P

</PRE>